Related Experiment Video
Updated: May 26, 2025
Prospecting Microbial Strains for Bioremediation and Probiotics Development for Metaorganism Research and Preservation
Published on: October 31, 2019
Metabolomic and genomic insights into Micromonospora carbonacea subsp. caeruleus for anti-colorectal compound
Tepakorn Kongsaya1,2, Nuttaporn Emthomya1,2, Chananan Ngamcharungchit1,2
1Department of Biotechnology, Faculty of Science, Mahidol University, Bangkok, 10400, Thailand.
Abstract:
Cancer is a predominant contributor to global morbidity and mortality, affecting populations worldwide. Marine Micromonospora species have been identified as significant sources of anticancer compounds. This work aimed to perform a polyphasic approach of isolated strain and conduct comparative metabolomic and genomic analyses to identify compounds with anticancer activity. The study utilized a polyphasic approach on isolated strains for anticancer compound identification. Taxonomic analysis of strain 2MTK254 revealed unique pigment and fatty acid patterns, designating it as a novel Micromonospora carbonacea subsp. caeruleus. Its crude extract displayed significant anti-colorectal activity (66.03% inhibition). Molecular network analysis classified metabolites into eight classes, highlighting a polycyclic tetramate macrolactams (PTMs) compound (P1, C29H38N2O4) with 99.31% inhibitory activity against HCT-116 cell lines (IC50 at 0.125 µM). Genome analysis identified 32 biosynthetic gene clusters (BGCs), including unique PTMs BGCs (83% similarity) linked to the P1 compound. Thus, M. carbonacea subsp. caeruleus 2MTK254 holds promise as a source of novel PTMs with anti-colorectal cancer potential. KEY POINTS: • A novel strain of Micromonospora carbonacea subsp. caeruleus 2MTK254 was isolated in Thailand • A new polycyclic tetramate macrolactam (PTM) with anticancer activity was identified in 2MTK254 • The genome of 2MTK254 has unique secondary metabolite gene clusters.
Insights
A novel marine bacterium, Micromonospora carbonacea subsp. caeruleus 2MTK254, produces a potent anticancer compound. This polycyclic tetramate macrolactam (PTM) shows high efficacy against colorectal cancer cells, offering new therapeutic potential.
Area of Science:
- Marine Microbiology
- Natural Products Chemistry
- Cancer Research
Background:
- Marine Micromonospora species are recognized for their anticancer compound production.
- Colorectal cancer remains a significant global health challenge, necessitating novel therapeutic strategies.
Purpose of the Study:
- To isolate and characterize novel marine Micromonospora strains.
- To identify and evaluate anticancer compounds from these isolates.
- To conduct genomic and metabolomic analyses for compound discovery.
Main Methods:
- Polyphasic taxonomic analysis of isolated strain 2MTK254.
- Metabolomic analysis using molecular networking.
- Genomic analysis to identify biosynthetic gene clusters (BGCs).
- In vitro anticancer activity assays against colorectal cancer cell lines.
Main Results:
- A novel subspecies, Micromonospora carbonacea subsp. caeruleus 2MTK254, was identified.
- The strain's crude extract exhibited significant anti-colorectal activity (66.03% inhibition).
- A novel polycyclic tetramate macrolactam (PTM), P1, demonstrated potent inhibition (99.31%) against HCT-116 cells (IC50 = 0.125 µM).
- Genome analysis revealed unique PTM BGCs associated with compound P1.
Conclusions:
- Micromonospora carbonacea subsp. caeruleus 2MTK254 is a promising source of novel PTMs.
- The identified PTM exhibits significant anti-colorectal cancer potential.
- Further investigation into these PTMs could lead to new cancer therapeutics.
